An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults
Phase of Trial: Phase I/II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs ABX 464 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Abivax
- 17 Mar 2017 Status changed from not yet recruiting to recruiting.
- 08 Dec 2016 Status changed from planning to not yet recruiting.
- 04 Feb 2015 New trial record